Full Press Release Details
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Jefferies Global Healthcare Conference
Presentation: Wednesday, June 5, 2024, at 3:30 p.m. ET at the Marriott Marquis New York, New York
Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the webcast here
Management will also participate in one-on-one meetings on Wednesday, June 5
Goldman Sachs 45th Annual Global Healthcare Conference
Presentation: Monday, June 10, 2024, at 3:20 p.m. ET at the Loews Miami Beach Hotel, Miami Beach, Florida
Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the webcast here
Management will also participate in one-on-one meetings during the conference
A webcast of both presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.
About Foghorn Therapeutics
Greg Dearborn, Foghorn Therapeutics Inc. (Investors)
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
Adam Silverstein, ScientPR (Media)